3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
103
Leukemia
53
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Leukemia, Monocytic, Acute
26
Leukemia, Erythroblastic, Acute
23
Congenital Abnormalities
23
Leukemia, Myelomonocytic, Acute
22
Leukemia, Megakaryoblastic, Acute
21
Myelodysplastic Syndromes
17
Lymphoma
12
Recurrence
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Leukemia, Biphenotypic, Acute
9
Lymphoma, Non-Hodgkin
6
Burkitt Lymphoma
6
Anemia, Refractory, with Excess of Blasts
6
Lymphoma, Large B-Cell, Diffuse
5
Leukemia, Promyelocytic, Acute
5
Blast Crisis
5
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Follicular
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Eosinophilic, Acute
4
Leukemia, Basophilic, Acute
4
Sarcoma, Myeloid
3
Neutropenia
3
Myeloproliferative Disorders
3
Lymphoma, Mantle-Cell
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
3
Interventions
blinatumomab
15
Cyclophosphamide
15
Cytarabine
14
Azacitidine
11
venetoclax
10
fludarabine
10
fludarabine phosphate
7
Methotrexate
7
Daunorubicin
7
Rituximab
6
Vincristine
5
Mercaptopurine
5
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Doxorubicin
3
Dexamethasone
3
Cladribine
3
Busulfan
3
Asparaginase
3
thymoglobulin
2
pembrolizumab
2
pegaspargase
2
nilotinib
2
midostaurin
2
daratumumab
2
Vindesine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Mitoxantrone
×
Other hematologic neoplasm
×
Clear all
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled